Argenx Stock - Thursday technical snapshot with ARGX near recent highs

Argenx stock sits not far below its recent record area on Nasdaq, with traders watching key technical levels around the 50-day and 200-day moving averages while analysts’ targets remain well above the current quote.

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 19:45 UTC. Details in the imprint.

Argenx (NL0010832176) is trading robustly on Nasdaq this week, holding close to the upper end of its recent range. The biotech name remains well covered by analysts and continues to attract attention after earlier-year clinical and regulatory milestones.

What prices show this week

On Wednesday’s close, Argenx shares on Nasdaq changed hands around the high-$800s, with one data provider showing a last price near $892.11, leaving the stock not far from its recent record region earlier this year.

That closing level implies a market capitalization of roughly $55.8 billion and a trailing price-earnings ratio close to 37, underlining the growth expectations investors still price into the autoimmune specialist.

Thursday’s chart and volatility picture

Shorter-term, the stock is described by technical services as trading sideways between near-term support and resistance bands, a setup that can favor range-bound strategies when momentum is muted.

Over the past month, Argenx shares have delivered solid technical performance while remaining within this band, and one quantitative screen highlights strong institutional ownership alongside a broadly positive bias from recent analyst ratings.

How analysts frame Argenx

Consensus data collated by market platforms point to an average 12-month target price above $1,020 for Argenx, implying upside from current trading levels if those projections are met.

Several large houses have reiterated positive stances in recent weeks, and some earlier in the quarter nudged targets higher after updated clinical data for the company’s lead drug platform in additional autoimmune indications.

Thursday focus on chart and technicals

For a Thursday lens, traders are watching how Argenx behaves around key moving averages on Nasdaq, particularly the 50-day and 200-day lines that many participants use as trend gauges.

With the quote still well above levels seen at the start of the year, but short of the most aggressive analyst targets, the current consolidation zone is an area where volumes and order-book dynamics may give clues to the next sustained move.

The product behind the stock

Argenx generates revenue from VYVGART, its FcRn-targeting therapy approved for generalized myasthenia gravis and other autoimmune diseases, along with the subcutaneous formulation VYVGART HYTRULO that expands administration options for eligible patients.

Where the stock trades today

Argenx shares (NL0010832176) trade on Nasdaq at about $892.11 as of 06/17/2026, 16:00 ET, according to recent quote data in USD.

Key facts on Argenx stock

• Company: argenx SE
• ISIN: NL0010832176
• WKN: A1W3MX
• Ticker: ARGX
• Venue: Nasdaq
• Price (as of 06/17/2026, 16:00 ET): 892.11 USD
• Market cap: 55.79 billion USD (as of 06/17/2026)
• Sector / Industry: Healthcare / Biotechnology
• Index membership: not a member of the S&P 500 or Nasdaq-100
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.